Premium
DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL‐B
Author(s) -
Davies A.J.,
Barrans S.,
Maishman T.,
Cummin T.E.,
Bentley M.,
Mamot C.,
Novak U.,
Caddy J.,
Hamid D.,
KazmiStokes S.H.,
Mcmillan A.,
Fields P.A.,
Pocock C.,
Kruger A.,
Collins G.,
Sha C.,
Clipson A.,
Wang M.,
Tooze R.M.,
Care M.A.,
Griffiths G.O.,
Du M.,
Westhead D.R.,
Burton C.,
Jack A.,
Johnson P.W.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_120
Subject(s) - diffuse large b cell lymphoma , bortezomib , medicine , chop , oncology , clinical endpoint , transcriptome , population , germinal center , lymphoma , progression free survival , gastroenterology , biology , b cell , clinical trial , immunology , overall survival , gene expression , multiple myeloma , genetics , gene , environmental health , antibody